Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of a Booster Dose of Pneumo 23® in 12 to 18 Months-Old Children Primed With Prevnar

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 12 to 18 months on the day of inclusion~* Informed consent form signed by the parent/legally acceptable representative and by an independent witness if requested by local Ethics Committee regulation or/and if the parent/legally acceptable representative is illiterate~* Child having completed the three-dose primary vaccination of Prevnar® in the hexavalent combined vaccine study (study A3L12).~* Subjects and parent/guardian able to attend all scheduled visits and comply with all study procedures~Exclusion Criteria:~* Participation in another clinical study investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the study vaccination~* Planned participation in another clinical study during the present study period~* Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term systemic corticosteroids therapy~* Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the study vaccine or to a vaccine containing any of the same substances~* Chronic illness at a stage that could interfere with study conduct or completion, in the opinion of the investigator~* Receipt of blood or blood-derived products since birth that might interfere with the assessment of immune response~* Receipt of any vaccine in the 4 weeks preceding the study vaccination~* Planned receipt of any vaccine in the 4 weeks preceding or following study vaccination~* History of seizures Known personal Human Immunodeficiency Virus (HIV), Hepatitis B (HB) antigen or Hepatitis C seropositivity~* History of pneumococcal infection (confirmed either clinically, serologically or microbiologically)~* Previous booster vaccination against the pneumococcal disease with either the study vaccine(s) or another vaccine~* Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding inclusion contraindicating IM vaccination~* Febrile illness (temperature ≥ 38°C) or moderate or severe acute illness/infection on the day of vaccination, according to investigator judgment.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 18 Months
- Healthy Volunteers: t

Study Arms:
- Group A (Type: EXPERIMENTAL): Pneumo 23
- Group B (Type: ACTIVE_COMPARATOR): Prevnar

Based on this trial design, predict the completion outcome and termination type (if applicable).